Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on...
ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on...
Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A...
Vamorolone is one of five treatments selected for the rare disease reimbursement pilot program.The program aims to shorten the National...
Tony Pullen steps down from the Board and will continue with the Company as an advisorVancouver, British Columbia--(Newsfile Corp. -...
Egetis Therapeutics’ lead asset, EMCITATE®, is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated...
Support the urgent need for brain research fundingHighlights:To advance brain research, the American Academy of Neurology has launched its year-end...
The FDA recognizes through this designation both the clinical evidence supporting daridorexant and the significant unmet medical need in pediatric...
Collaborative research projects will focus on studies of cancer dormancy and metastasisBRONX, N.Y., Nov. 3, 2026 /PRNewswire/ -- The National...
BEND, OR / ACCESS Newswire / November 3, 2026 / Reflecting record participation from partner veterinary clinics across the Pacific...
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of...
Partnership pairs Marvix AI's specialty-focused clinical documentation with Unlimited Systems' revenue cycle expertise, giving specialty practices a connected path from...
Rebecca M. Brown, MD, and Kavita Sarin, MD, PhD, will join management to discuss unmet needs and the treatment landscape...
First joint project launches a broader platform strategy for process orchestration across the clinical trial lifecycle BERLIN, Oct. 28, 2026...
Presented at the NORD Breakthrough Summit, the findings show EDS patients wait a median of nearly eight years for a...
KFSH Mobile Stroke Unit KFSH emergency staff beside a mobile stroke unit in Riyadh RIYADH, Saudi Arabia, Oct. 24, 2026...
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd., a subsidiary of Claritas HealthTech Ltd, today announced that...
Submission marks an important milestone towards bringing a new treatment option to patients with DMD in South Korea. Vamorolone has already...
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower...
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower...
Ad hoc announcement pursuant to Art. 53 LRBasel, 22 October 2026 Roche continues strong momentum in the third quarter with...